Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 107


Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer.

Steel JC, Di Pasquale G, Ramlogan CA, Patel V, Chiorini JA, Morris JC.

Mol Ther. 2013 Mar;21(3):680-7. doi: 10.1038/mt.2012.260. Epub 2013 Jan 8.


Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.

Sakai Y, Morrison BJ, Burke JD, Park JM, Terabe M, Janik JE, Forni G, Berzofsky JA, Morris JC.

Cancer Res. 2004 Nov 1;64(21):8022-8.


Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.

Wang X, Wang JP, Rao XM, Price JE, Zhou HS, Lachman LB.

Breast Cancer Res. 2005;7(5):R580-8. Epub 2005 May 23.


Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.

Xie Y, Chen Y, Ahmed KA, Li W, Ahmed S, Sami A, Chibbar R, Tang X, Tao M, Xu J, Xiang J.

Cancer Gene Ther. 2013 Oct;20(10):590-8. doi: 10.1038/cgt.2013.60. Epub 2013 Sep 20.


Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.

Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB.

Breast Cancer Res. 2004;6(4):R275-83. Epub 2004 Apr 7.


Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2.

Mossoba ME, Walia JS, Rasaiah VI, Buxhoeveden N, Head R, Ying C, Foley JE, Bramson JL, Fowler DH, Medin JA.

Mol Ther. 2008 Mar;16(3):607-17. doi: 10.1038/ Epub 2008 Jan 8.


Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.

Chen Z, Huang H, Chang T, Carlsen S, Saxena A, Marr R, Xing Z, Xiang J.

Cancer Gene Ther. 2002 Sep;9(9):778-86.


The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.

Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM.

Cancer Res. 2001 Feb 1;61(3):880-3.


Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice.

Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Cipriani B, Forni G, Monaci P.

Int J Cancer. 2007 Feb 1;120(3):574-84.


Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.

Moran TP, Burgents JE, Long B, Ferrer I, Jaffee EM, Tisch RM, Johnston RE, Serody JS.

Vaccine. 2007 Sep 4;25(36):6604-12. Epub 2007 Jul 17.


HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.

Chan T, Sami A, El-Gayed A, Guo X, Xiang J.

Gene Ther. 2006 Oct;13(19):1391-402. Epub 2006 May 25.


Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.

Wang L, Xie Y, Ahmed KA, Ahmed S, Sami A, Chibbar R, Xu Q, Kane SE, Hao S, Mulligan SJ, Xiang J.

Breast Cancer Res Treat. 2013 Jul;140(2):273-84. doi: 10.1007/s10549-013-2626-7. Epub 2013 Jul 24.


Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.

Yo YT, Hsu KF, Shieh GS, Lo CW, Chang CC, Wu CL, Shiau AL.

Cancer Gene Ther. 2007 Nov;14(11):904-17. Epub 2007 Aug 17.


Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8⁺ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice.

Chen Y, Xie Y, Chan T, Sami A, Ahmed S, Liu Q, Xiang J.

Cancer Gene Ther. 2011 Jul;18(7):489-99. doi: 10.1038/cgt.2011.18. Epub 2011 May 13.


A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.

Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY, Sakaguchi S, Kang CY.

Cancer Res. 2007 Aug 1;67(15):7477-86.


Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.

Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y.

Clin Cancer Res. 2009 Jul 15;15(14):4612-21. doi: 10.1158/1078-0432.CCR-08-3321. Epub 2009 Jul 7.


Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.

Gritzapis AD, Voutsas IF, Baxevanis CN.

Cancer Immunol Immunother. 2012 Mar;61(3):397-407. doi: 10.1007/s00262-011-1113-4. Epub 2011 Sep 18.


Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells.

Xin KQ, Mizukami H, Urabe M, Toda Y, Shinoda K, Yoshida A, Oomura K, Kojima Y, Ichino M, Klinman D, Ozawa K, Okuda K.

J Virol. 2006 Dec;80(24):11899-910. Epub 2006 Sep 27.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk